Evidence map›Paper›PMID 37349810›Full record

ArticleBiomaterials research2023

NK cells encapsulated in micro/macropore-forming hydrogels via 3D bioprinting for tumor immunotherapy.

Dahong Kim, Seona Jo, Dongjin Lee, Seok-Min Kim, Ji Min Seok, Seon Ju Yeo, Jun Hee Lee, Jae Jong Lee, Kangwon Lee, Tae-Don Kim and 1 more

Open access · goldAbstract read
In one paragraph

Article in Biomaterials research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. [Biomaterials of different sizes for enhanced adoptive cell transfer therapy in solid tumors].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025
    Review
  12. Review
  13. Review
  14. Review
  15. Biomaterial-Based Therapeutic Delivery of Immune Cells.Advanced healthcare materials · 2025
    Review
  16. Review
  17. Pioneering biomimetic biomaterial for leukemia therapy enhancement: a review.Frontiers in bioengineering and biotechnology · 2025
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Dahong KimNano Convergence & Manufacturing Systems, Korea Institute of Machinery and Materials (KIMM), Daejeon, 34103, Republic of Korea.
Seona JoImmunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, 34141, Republic of Korea.
Dongjin LeeNano Convergence & Manufacturing Systems, Korea Institute of Machinery and Materials (KIMM), Daejeon, 34103, Republic of Korea.
Seok-Min KimImmunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, 34141, Republic of Korea.
Ji Min SeokNano Convergence & Manufacturing Systems, Korea Institute of Machinery and Materials (KIMM), Daejeon, 34103, Republic of Korea.
Seon Ju YeoNano Convergence & Manufacturing Systems, Korea Institute of Machinery and Materials (KIMM), Daejeon, 34103, Republic of Korea.
Jun Hee LeeNano Convergence & Manufacturing Systems, Korea Institute of Machinery and Materials (KIMM), Daejeon, 34103, Republic of Korea.
Jae Jong LeeNano Convergence & Manufacturing Systems, Korea Institute of Machinery and Materials (KIMM), Daejeon, 34103, Republic of Korea.
Kangwon LeeDepartment of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, Republic of Korea.
Tae-Don Kim *Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, 34141, Republic of Korea. tdkim@kribb.re.kr.
Su A Park *Nano Convergence & Manufacturing Systems, Korea Institute of Machinery and Materials (KIMM), Daejeon, 34103, Republic of Korea. psa@kimm.re.kr.ORCID http://orcid.org/0000-0001-5878-8054
Korea Institute of Machinery & Materials · KRSeoul National University · KRKorea Research Institute of Bioscience and Biotechnology · KRInstitute for Basic Science · KR

Funding

NRF 2020M3H4A1A02084828NST CAP-18-02-KRIBB and CRC22021-200
6 · The paper itself

Abstract

backgroundPatients face a serious threat if a solid tumor leaves behind partial residuals or cannot be completely removed after surgical resection. Immunotherapy has attracted attention as a method to prevent this condition. However, the conventional immunotherapy method targeting solid tumors, that is, intravenous injection, has limitations in homing in on the tumor and in vivo expansion and has not shown effective clinical results.

methodTo overcome these limitations, NK cells (Natural killer cells) were encapsulated in micro/macropore-forming hydrogels using 3D bioprinting to target solid tumors. Sodium alginate and gelatin were used to prepare micro-macroporous hydrogels. The gelatin contained in the alginate hydrogel was removed because of the thermal sensitivity of the gelatin, which can generate interconnected micropores where the gelatin was released. Therefore, macropores can be formed through bioprinting and micropores can be formed using thermally sensitive gelatin to make macroporous hydrogels.

resultsIt was confirmed that intentionally formed micropores could help NK cells to aggregate easily, which enhances cell viability, lysis activity, and cytokine release. Macropores can be formed using 3D bioprinting, which enables NK cells to receive the essential elements. We also characterized the functionality of NK 92 and zEGFR-CAR-NK cells in the pore-forming hydrogel. The antitumor effects on leukemia and solid tumors were investigated using an in vitro model.

conclusionWe demonstrated that the hydrogel encapsulating NK cells created an appropriate micro-macro environment for clinical applications of NK cell therapy for both leukemia and solid tumors via 3D bioprinting. 3D bioprinting makes macro-scale clinical applications possible, and the automatic process shows potential for development as an off-the-shelf immunotherapy product. This immunotherapy system could provide a clinical option for preventing tumor relapse and metastasis after tumor resection. Micro/macropore-forming hydrogel with NK cells fabricated by 3D bioprinting and implanted into the tumor site.

Indexed as

3D bioprintingImmunotherapyMicro/macropore-formingNK cellsSolid tumor

Identifiers

PMID37349810
PMCPMC10286468
OpenAlexW4381684083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.